Generoath Co., Ltd., and Bestblue Inc. v. Jay Madan, an individual, Biotos Therapeutics, Inc., a Delaware Corporation, John Does (1-20) and ABC Corporations (1-10)

CourtDistrict Court, D. New Jersey
DecidedMay 19, 2026
Docket2:24-cv-04520
StatusUnknown

This text of Generoath Co., Ltd., and Bestblue Inc. v. Jay Madan, an individual, Biotos Therapeutics, Inc., a Delaware Corporation, John Does (1-20) and ABC Corporations (1-10) (Generoath Co., Ltd., and Bestblue Inc. v. Jay Madan, an individual, Biotos Therapeutics, Inc., a Delaware Corporation, John Does (1-20) and ABC Corporations (1-10)) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Generoath Co., Ltd., and Bestblue Inc. v. Jay Madan, an individual, Biotos Therapeutics, Inc., a Delaware Corporation, John Does (1-20) and ABC Corporations (1-10), (D.N.J. 2026).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

GENEROATH CO., LTD., and Civil Action No. 24-4520 BESTBLUE INC., Plaintiffs, v. OPINION

JAY MADAN, an individual, May 19, 2026 BIOTOS THERAPEUTICS, INC., a

Delaware Corporation, JOHN DOES (1-20) and ABC CORPORATIONS (1-10)

Defendants.

SEMPER, District Judge. THIS MATTER comes before the Court upon a Motion for Default Judgment and Sanctions filed by Plaintiffs Generoath Co., LTD. and Bestblue Inc. (“Generoath” and “Bestblue” or, together, “Plaintiffs”) against Jay Madan and Biotos Therapeutics, Inc. (“Madan” and “Biotos” or, together, “Defendants”) pursuant to Federal Rule of Civil Procedure (“Rule”) 55(b)(2). (ECF 35-1, “Motion” or “Mot.”) The Court has decided this Motion upon submission, without oral argument, pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1. For the reasons stated below, Plaintiffs’ Motion is DENIED WITHOUT PREJUDICE. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY1 This matter arises from Plaintiffs’ claims of breach of contract, common law conversion, embezzlement, unjust enrichment, constructive trust, fraud or misrepresentation, corporation

1 The facts and procedural history are drawn from the briefings (ECF Nos. 1, 3, 4, 5, 6, 10, 14, 22, 24, 25, 28, 34, 35) and documents integral to or relied upon by the briefings. See In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1426 (3d Cir. 1997). A district court may consider dissolution pursuant to N.J. Stat. Ann. § 14A:12- 7(1)(c), replevin, fraudulent conveyance, and federal RICO, and now, breach of settlement, against Defendants. (ECF 1, “Complaint” or “Compl.” ¶¶ 49-118; Mot. at 2-3.) Plaintiffs are Generoath, a biopharmaceutical company focused on the development of gene therapies for neurodegenerative diseases, and Bestblue, a

biopharmaceutical investment company. (Compl. ¶¶ 12-13.) Generoath is a foreign corporation that is both organized under the laws of and maintains its principal place of business in South Korea. (Id. ¶ 1.) Bestblue is both organized under the laws of and maintains its principal place of business in Oregon. (Id. ¶ 2.) Defendant Madan is an individual domiciled in North Carolina. (Id. ¶ 3.) Defendant Biotos is a corporation incorporated in Delaware and headquartered in North Carolina. (Id. ¶ 4.) In 2021, Generoath sought to expand its business operations by attracting investors to the United States. (Id. ¶ 14.) In October 2021, Generoath appointed an agent, Young Moon, to identify a U.S. business partner. (Id. ¶ 15.) Young Moon is based in New Jersey. (Id.) Young Moon contacted Madan and proposed the establishment of a U.S. subsidiary to facilitate

investment, research, and development. (Id. ¶ 16.) On November 15, 2021, Young Moon and Madan met at the Marriot Hotel in Newark, New Jersey to discuss Generoath’s new venture. (Id. ¶ 17.) At the meeting, Madan represented that he has “BD experience in global Big Pharma,” experience in listing and exiting biotech ventures, and that he founded a biotech company called Innovate Biopharma. (Id. ¶ 18.) On May 25, 2022, representatives from Generoath met with Madan in Boston, Massachusetts, to discuss Generoath’s research and development status. (Id. ¶

“exhibits attached to the complaint and matters of public record” as well as “an undisputedly authentic document that a defendant attaches as an exhibit to a motion to dismiss if the plaintiff’s claims are based on the document.” Pension Ben. Guar. Corp. v. White Consol. Indus., Inc., 998 F.2d 1192, 1196 (3d Cir. 1993). 20.) Based on these discussions, the parties decided to establish Generoath’s U.S. subsidiary, Biotos, by July 2022. (Id. ¶ 21.) Generoath offered Madan 10% equity in Biotos for his active role in the new venture. (Id. ¶ 22.) Madan requested a loan of $500,000.00 (which was later adjusted to $300,000 in total),

and the parties discussed a licensing agreement from Generoath to the newly formed U.S. subsidiary and the composition of a board of directors. (Id. ¶ 23.) On July 15, 2022, Generoath and Madan executed a consultant agreement requiring Generoath to pay Madan $15,000 monthly in exchange for his assistance in creating Biotos. (Id. ¶¶ 24-25.) From July 2022 to April 2023, Generoath wired $15,000 monthly to Madan, totaling $150,000. (Id. ¶¶ 26, 43.) On August 4, 2022, Madan established Biotos as Generoath’s U.S. subsidiary. (Id. ¶ 27.) On January 18, 2023, Generoath provided Biotos with a $249,000 loan. (Id. ¶ 32.) In February 2023, Bestblue wired Biotos an additional $51,000 loan under an agreement via email. (Id. ¶ 33.) In February 2023, Generoath’s representative met with Madan in New York City to discuss progress in investor recruitment. (Id. ¶ 34.) Doubting Madan’s contributions, Generoath

suspended his consultancy payments pending a satisfactory report of his activities. (Id. ¶ 35.) By April 2023, Generoath demanded a detailed activity report from Madan, ceasing consultancy payments due to insufficient documentation. (Id. ¶ 36.) In July 2023, Madan proposed repaying the $249,000 loan and suggested modifications to the consultancy agreement. (Id. ¶ 38.) By November 2023, Generoath formally demanded repayment of the $249,000 loan, which Madan did not acknowledge. (Id. ¶ 39.) In January 2024, Generoath and Bestblue reiterated their demand for loan repayment, receiving no response from Madan. (Id. ¶ 40.) Plaintiffs also allege Madan neglected to complete corporate documentation establishing that Biotos would be owned by certain shareholders, including Generoath and Bestblue, and failed to issue stock certificates and other foundational documents. (Id. ¶¶ 28-29.) As a result, Plaintiffs commenced this action against Defendants on April 3, 2024. (See generally id.) Defendant Madan was served with the Complaint and summons in this matter on

April 22, 2024, and Defendant Biotos was served on April 26, 2024. (ECF 3; ECF 4.) After Defendants failed to respond to the Complaint, Plaintiffs petitioned the Clerk of the Court for an entry of default on May 21, 2024. (ECF 5.) The Clerk of the Court entered default against Defendants on May 22, 2024. (Id.) Defendant Madan then filed a Motion to Dismiss the Complaint for improper venue on May 22, 2024. (ECF 6, “Motion to Dismiss”). This Court denied Madan’s Motion to Dismiss on October 11, 2024. (ECF 10.) The parties entered into a settlement agreement on January 31, 2025. (ECF 22.) Defendants agreed to pay Plaintiff Generoath $200,000 by February 18, 2025, and the full judgment amount of $250,000 if they failed to meet that deadline. (ECF 22.) Defendants also agreed to pay Plaintiff Bestblue $50,000 by February 11, 2025. (ECF 22-1.) On February 10,

2025, the Court administratively terminated the case for 60 days pending consummation of the settlement, (ECF 21), and on April 15, 2025, the Clerk of the Court dismissed the case with prejudice. (ECF 24.) On May 15, having received no settlement payments from Defendants, Plaintiffs filed a Motion to Vacate the Order of Dismissal. (ECF 25.) The Court ordered Defendants to pay the entire settlement amount to Plaintiffs by July 8, 2025. (ECF 28.) After Defendants continuously failed to pay the settlement, the Court again ordered Defendants to pay the settlement by September 5, 2025.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

World-Wide Volkswagen Corp. v. Woodson
444 U.S. 286 (Supreme Court, 1980)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Chambers v. Nasco, Inc.
501 U.S. 32 (Supreme Court, 1991)
Tozer v. Charles A. Krause Milling Co.
189 F.2d 242 (Third Circuit, 1951)
Comdyne I, Inc. v. Corbin
908 F.2d 1142 (Third Circuit, 1990)
Tracinda Corp. v. Daimlerchrysler Ag
502 F.3d 212 (Third Circuit, 2007)
O'CONNOR v. Sandy Lane Hotel Co., Ltd.
496 F.3d 312 (Third Circuit, 2007)
Metcalfe v. Renaissance Marine, Inc.
566 F.3d 324 (Third Circuit, 2009)
Chanel, Inc. v. Gordashevsky
558 F. Supp. 2d 532 (D. New Jersey, 2008)
Milad Allaham v. Fadi Naddaf
635 F. App'x 32 (Third Circuit, 2015)
Daniel Marino v. Usher
673 F. App'x 125 (Third Circuit, 2016)
Hritz v. Woma Corp.
732 F.2d 1178 (Third Circuit, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
Generoath Co., Ltd., and Bestblue Inc. v. Jay Madan, an individual, Biotos Therapeutics, Inc., a Delaware Corporation, John Does (1-20) and ABC Corporations (1-10), Counsel Stack Legal Research, https://law.counselstack.com/opinion/generoath-co-ltd-and-bestblue-inc-v-jay-madan-an-individual-biotos-njd-2026.